LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,053
تعداد مقالات9,692
تعداد مشاهده مقاله12,902,620
تعداد دریافت فایل اصل مقاله6,147,542
Zhu, Miao, Zhang, Jun, Shi, Qingqing, Sun, Xing, Wang, Haibo, Sun, Mei, Liu, Yanqing. (1402). Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report. سامانه مدیریت نشریات علمی, (), -. doi: 10.22034/iji.2023.99254.2629
Miao Zhu; Jun Zhang; Qingqing Shi; Xing Sun; Haibo Wang; Mei Sun; Yanqing Liu. "Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report". سامانه مدیریت نشریات علمی, , , 1402, -. doi: 10.22034/iji.2023.99254.2629
Zhu, Miao, Zhang, Jun, Shi, Qingqing, Sun, Xing, Wang, Haibo, Sun, Mei, Liu, Yanqing. (1402). 'Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report', سامانه مدیریت نشریات علمی, (), pp. -. doi: 10.22034/iji.2023.99254.2629
Zhu, Miao, Zhang, Jun, Shi, Qingqing, Sun, Xing, Wang, Haibo, Sun, Mei, Liu, Yanqing. Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report. سامانه مدیریت نشریات علمی, 1402; (): -. doi: 10.22034/iji.2023.99254.2629

Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report

Iranian Journal of Immunology
مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 02 آبان 1402    اصل مقاله (1.66 M)
نوع مقاله: Case Report
شناسه دیجیتال (DOI): 10.22034/iji.2023.99254.2629
نویسندگان
Miao Zhu1، 2؛ Jun Zhang2؛ Qingqing Shi2؛ Xing Sun2؛ Haibo Wang1؛ Mei Sun2؛ Yanqing Liu* 1
1The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, Jiangsu, China.
2Clinical Medical College, Yangzhou University, Yangzhou 225001, China.
چکیده
Hemophagocytic lymphohistiocytosis (HLH) is a fatal clinical syndrome. The most common cause of secondary HLH is Epstein-Barr virus (EBV) infection. EBV-HLH is a common clinical disease with high mortality, easy relapse, and poor prognosis. Therefore, treating EBV-HLH with T and B lymphocyte involvement is challenging, and selecting an appropriate treatment regimen is critical. Moreover, research on how to evaluate the recurrence index after remission is scarce. In this study, we reported a case of EBV-HLH successfully treated with programmed cell death protein-1 (PD-1) inhibitor in combination with rituximab. The regimen had a good curative effect, and we successfully detected the trend of early recurrence. Our findings indicated that PD-1 inhibitor in combination with rituximab may help to treat EBV-HLH and maintain EBV-infected T and B whole-line lymphocytes.
کلیدواژه‌ها
CD20 Monoclonal Antibody؛ Epstein-Barr Virus؛ Hemophagocytic Lymphohistiocytosis؛ Programmed Cell Death Protein-1؛ Salvage Therapy
آمار
تعداد مشاهده مقاله: 210
تعداد دریافت فایل اصل مقاله: 75


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب